NeuroPace develops and commercializes the RNS System, an implantable responsive neurostimulation device for people with drug-resistant focal epilepsy. The closed-loop system monitors brain activity and delivers stimulation when abnormal patterns are detected, rather than providing continuous open-loop stimulation alone. It serves epilepsy patients and specialists in neuromodulation and seizure care, primarily in the United States.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 19.5 | — | -8.7 | — |
| Q3 2025 | 27.4 | — | -3.5 | — |
| Q4 2025 | 26.6 | — | -2.7 | — |
| Q1 2026 | 22.1 | — | -6.7 | — |
| Q2 2026 | 22.8 | 17.1% | -6.2 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: K&F Growth Acquisition Corp. II (KFII), Ovid Therapeutics Inc. (OVID), YD Bio Ltd (YDES), AMC Global Media Inc. (AMCX), Churchill Capital Corp XIII (XIII), Oportun Financial Corporation (OPRT)